Advertisement
Screener

Zevra Therapeutics, Inc. (ZVRA) Investments, Fair Value Disclosure

2.8 / 5 stars · 68/120 Roast Me

Zevra Therapeutics, Inc. Investments, Fair Value Disclosure

Zevra Therapeutics, Inc. (ZVRA) had Investments, Fair Value Disclosure of $43.30 million as of 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Notes › Fair Value Disclosures

us-gaap:InvestmentsFairValueDisclosure · last filed 2026-08-05

  • 2026-06-30: Investments, Fair Value Disclosure $43.30M.
  • 2026-03-31: Investments, Fair Value Disclosure $82.60M.
  • 2025-12-31: Investments, Fair Value Disclosure $176.50M.
  • 2025-09-30: Investments, Fair Value Disclosure $175.90M.
Period endInvestments, Fair Value DisclosureInvestments, Fair Value Disclosure as first filed
2026-06-30$43.30M
10-Q · filed 2026-08-05
2026-03-31$82.60M
10-Q · filed 2026-05-06
2025-12-31$176.50M
10-Q · filed 2026-08-05
2025-09-30$175.90M
10-Q · filed 2025-11-05
2025-06-30$170.00M
10-Q · filed 2025-08-12
2025-03-31$31.40M
10-Q · filed 2025-05-13
2024-12-31$41.70M
10-K · filed 2026-03-09
2024-09-30$41.40M
10-Q · filed 2024-11-13
2024-06-30$10.00M
10-Q · filed 2024-08-14
2024-03-31$9.90M
10-Q · filed 2024-05-09
2023-12-31$24.70M
10-K · filed 2025-03-12
2023-09-30$39.70M
10-Q · filed 2023-11-07
2023-06-30$20.70M
10-Q · filed 2023-08-14
2023-03-31$34.40M
10-Q · filed 2023-05-15
2022-12-31$16.90M
10-K · filed 2024-04-01
2021-12-31$14.90M
10-K · filed 2023-03-07
$15.40M
10-K · filed 2022-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
Climb Bio, Inc. (CLYM)United States$0.683B-13.03
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
IRONWOOD PHARMACEUTICALS INC (IRWD)United States$0.694B5.37
Shattuck Labs, Inc. (STTK)United States$0.634B-13.30
Nuvectis Pharma, Inc. (NVCT)United States$0.705B-17.53
Verastem, Inc. (VSTM)United States$0.706B-1.71
Neurogene Inc. (NGNE)$0.625B-4.46
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25